Article

De novo pyrimidine biosynthesis inhibition synergizes with BCL-X <sub>L</sub> targeting in pancreatic cancer

2024-05-21

Abstract excerpt

Oncogenic KRAS, the genetic driver of 90% of pancreatic adenocarcinoma (PDAC), induces a metabolic rewiring characterized, in part, by dependency on de novo pyrimidine biosynthesis. Pharmacologic inhibition of dihydroorotate dehydrogenase (DHODH), an enzyme in the de novo pyrimidine synthesis pathway, delays pancreatic tumor growth in vivo; however, limited monotherapy efficacy suggests compensatory pathways and t...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: be77435f-838a-57cb-961b-1548ec38b873
DOI: 10.1101/2024.05.17.594738

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

De novo pyrimidine biosynthesis inhibition synergizes with BCL-X <sub>L</sub> targeting in pancreatic cancerDOI 10.1101/2024.05.17.594738Read

De novo pyrimidine biosynthesis inhibition synergizes with BCL-XL targeting in pancreatic cancerSemantic proximity Read

Dependence on the Pyrimidine Biosynthetic Enzyme DHODH Is a Synthetic Lethal Vulnerability in Mutant KRAS-Driven Cancers.Semantic proximity Read

Vertical RAS-pathway inhibition in pancreatic cancer drives therapeutically exploitable mitochondrial alterationsSemantic proximity Read

ISL2 is an epigenetically silenced tumor suppressor and regulator of metabolism in pancreatic cancerSemantic proximity Read

DNAJA1 Dysregulates Metabolism Promoting an Antiapoptotic Phenotype in Pancreatic Ductal Adenocarcinoma.Semantic proximity Read

Posttranscriptional Upregulation of IDH1 by HuR Establishes a Powerful Survival Phenotype in Pancreatic Cancer Cells.Semantic proximity Read

Targeting both the enzymatic and non-enzymatic functions of DHODH as a therapeutic vulnerability in c-Myc-driven cancerSemantic proximity Read

Changes in the Transcriptome and Synthetic Lethal Dependencies Following <i>KRAS</i> Mutant Expression Reveal Profound Tissue-SpecificitySemantic proximity Read

Targeted CRISPR screening identifies PRMT5 as synthetic lethality combinatorial target with gemcitabine in pancreatic cancer cellsSemantic proximity Read

USP25 promotes pathological HIF-1-driven metabolic reprogramming and is a potential therapeutic target in pancreatic cancerSemantic proximity Read

Targeted CRISPR screening identifies PRMT5 as synthetic lethality combinatorial target with gemcitabine in pancreatic cancer cellsSemantic proximity Read

Cytidine deaminase-dependent mitochondrial biogenesis as a potential vulnerability in pancreatic cancer cellsSemantic proximity Read